Merck & Co Inc said on Wednesday the U.S. government has agreed to pay about US$1.2 billion for 1.7 million courses of its experimental COVID-19 treatment, if it is proven to work in an ongoing large trial and authorized by U.S. regulators.
The oral antiviral treatment, molnupiravir, aims to stop COVID-19 from progressing and can be given early in the course of the disease, similar to Tamiflu to treat influenza.
The treatment course being tested in the trial is an oral dose given every 12 hours for five days.
Merck expects to have more than 10 million courses of the therapy available by the end of this year and said it was in discussions with other countries interested in advance purchase agreements for molnupiravir.
The company, which is developing the drug with Ridgeback Biotherapeutics, is assessing the treatment in a late-stage trial in non-hospitalized patients to see if it reduces the risk of hospitalization or death.
Data from the trial, which plans to enroll a total of 1,850 patients globally, are expected in the fall of 2021, according to the U.S. Department of Health and Human Services.
Other antiviral drugs also contending to be the first treatment aimed at the cause of COVID-19 include Pfizer Inc’s PF-07321332 and Roche Holding AG’s AT-527.
If successful, Merck said it expects to file for the emergency use authorization of molnupiravir in the second half of 2021 at the earliest.
Merck has focused on its treatment after two COVID-19 vaccines it was developing failed to generate the necessary immune responses in early testing, prompting it to abandon them in January.
The drugmaker announced a change of plans and said in April it would no longer pursue use of molnupiravir in hospitalized patients.
Jennifer Lopez To Star In Netflix’s Sci-Fi Thriller ‘Atlas’
Iranian election officials prepare ballot boxes
Android 12 Features You’ll Love
Biden to announce 300M COVID-19 shots given in 150 days
Blasts in Myanmar’s biggest city kill 2, destroy army truck
Middle East6 days ago
Saudi Arabia bars foreign travellers from Hajj over COVID19
Health7 days ago
U.S. FDA asks J&J to discard millions of COVID-19 vaccine doses
Football6 days ago
Christian Eriksen: Denmark midfielder ‘awake’ after collapsing on pitch
Weird6 days ago
Cape Cod diver left with a whale of a tale after a humpback spat him out
South America6 days ago
Peru’s Castillo on verge of winning presidency after tight race
Other6 days ago
Human Cells Can Write RNA Sequences Into DNA
Other5 days ago
Athletes told to take courtesy condoms home amid physical distancing rules in Olympic Village
Lifestyle4 days ago
Saudi ministry: Women can register for Hajj with other women without male guardian